Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Total Liabilities for 9 consecutive years, with $396.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 13.11% year-over-year to $396.5 million, compared with a TTM value of $396.5 million through Sep 2025, up 13.11%, and an annual FY2024 reading of $355.4 million, up 34.67% over the prior year.
  • Total Liabilities was $396.5 million for Q3 2025 at Autolus Therapeutics, up from $374.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $396.5 million in Q3 2025 and bottomed at -$214.5 million in Q2 2022.
  • Average Total Liabilities over 5 years is $229.1 million, with a median of $244.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities increased 9.54% in 2021, then soared 203.33% in 2023.
  • Year by year, Total Liabilities stood at $92.2 million in 2021, then surged by 107.72% to $191.6 million in 2022, then skyrocketed by 37.74% to $263.9 million in 2023, then soared by 34.67% to $355.4 million in 2024, then grew by 11.56% to $396.5 million in 2025.
  • Business Quant data shows Total Liabilities for AUTL at $396.5 million in Q3 2025, $374.5 million in Q2 2025, and $375.2 million in Q1 2025.